Trial · NCT02406209
Adverse events81
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 81
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Iridocyclitis | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Iridocyclitis | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Iridocyclitis | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 1 | 14 | |
| other | Conjunctival haemorrhage | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Conjunctival haemorrhage | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Conjunctival haemorrhage | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Cystoid macular oedema | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Cystoid macular oedema | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Cystoid macular oedema | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Eye inflammation | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Eye inflammation | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Eye inflammation | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Eye pruritus | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 1 | 15 | |
| other | Eye pruritus | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 0 | 16 | |
| other | Eye pruritus | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Lacrimation increased | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 1 | 15 | |
| other | Lacrimation increased | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 0 | 16 | |
| other | Lacrimation increased | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Macular oedema | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Macular oedema | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02406209/events